The Federal Trade Commission has approved Boston Scientific’s US$4 billion acquisition of British medtech company BTG, according to a regulatory filing.
Other antitrust authorities, such as the Federal Competition Authority of Austria and the National Authority for Markets and Competition in Spain, cleared the takeover in the past few weeks, according to the filing. BTG shareholders approved the purchase in March.
The fate of the deal is now in the hands of a British court, where a hearing is scheduled for August 15, 2019. If the court agrees to the acquisition, it could close August 19, with BTG shares canceled the next day.
Full Content: Investis
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
